Table 2.

Description of gravid, ABO blood group and malaria complications among the study groups

Dependant variables	MFC	UM	SM	Pvalue
	n = 60 (32.3%)	n = 62 (33.3%)	n = 64 (34.4%)
Gravidae				<0.001
Primigravidae	4 (6.7%)	54 (87.1%)	56 (87.5%)
n = 114 (61.3%)
Multigravidae	56 (93.3%)	8 (12.9%)	8 (12.5%)
n = 72 (38.7%)
ABO				<0.001
O n = 124 (66.7%)	44 (73.3%)	37 (59.7%)	43 (67.2%)
A n = 20 (10.8%)	8 (13.3%)	4 (6.5%)	8 (12.5%)
B n = 30 (16.1%)	4 (6.7%)	18 (29%)	8 (12.5%)
AB n = 12 (6.5%)	4 (6.7%)	3 (4.8%)	5 (7.8%)
Malaria complications				<0.001
No complications	60 (100%)	62 (100%)	0 (0%)
Anaemia	0 (0%)	0 (0%)	49 (76.6%)
Cerebral malaria	0 (0%)	0 (0%)	8 (12.5%)
Hypoglycaemia	0 (0%)	0 (0%)	7 (10.9%)
Treatment				<0.001
No treatment	60 (100%)	0 (0%)	0 (0%)
Quinine	0 (0%)	43 (69.4%)	0 (0%)
ACT*	0 (0%)	19 (30.6%)	0 (0%)
Artesunate plus quinine	0 (0%)	0 (0%)	64 (100%)

*Artemisinin-based combination therapy (ACT).